🔴 MBX Biosciences is trading 4.22% down as biotech stocks weaken

MBX Biosciences is trading 4.22% lower at $56.07, with biotech-sector weakness the likeliest explanation.

• On October 6, 2026, XBI was down 2.50%, while major U.S. indexes were higher.
• No clear company-specific announcement explaining the decline surfaced. Recent company coverage instead referenced earlier news and analyst activity, including a Guggenheim price-target increase reported October 2.